
|Videos|December 14, 2017
Results for the Combination of Selinexor and Daratumumab in Multiple Myeloma
Author(s)Cristina Gasparetto, MD
Cristina Gasparetto, MD, associate professor, head of the myeloma program, Duke University Medical Center, discusses a phase 1b study to assess the combination of selinexor and daratumumab in patients with relapsed/refractory multiple myeloma previously exposed to proteasome inhibitors and immunomodulatory drugs during the 2017 ASH Annual Meeting.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
Managing Toxicity and Safety of Belzutifan in ccRCC
3
Spotlighting Sequencing and Biomarkers in Bladder Cancer Management
4
Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment
5



















